Revvity Inc. (NYSE: RVTY) stock is trading lower after the company’s second-quarter 2025 earnings report, which included a trimmed profit forecast for the year. The company reported second-quarter sales of $720.28 million, exceeding the consensus estimate. Adjusted earnings were $1.18, but adjusted operating income and profit margin declined. Revenue in the life sciences segment increased by 5%, driven by growth in Signals Software. Diagnostics sales also increased, but the company lowered its adjusted earnings forecast for 2025. Revvity expects full-year organic growth to be lower than previously projected due to challenges in the market, including a recent policy change in China impacting diagnostic sales. Revvity stock is down 9.98% to $93.32.

Read more at Yahoo Finance: Revvity Slashes Outlook As China Policy Deals Diagnostics Blow